PharmAla Biotech Introduces Phenesafe AI Platform for Discovery of Novel Phenethylamine Compounds
Friday, May 16, 2025
PharmAla Biotech Holdings Inc, a biotechnology firm dedicated to the research, development, and manufacturing of LaNeo™ MDMA and new derivatives within the MDXX compound class, has officially launched its Phenesafe AI platform.
Phenesafe AI is a specialised artificial intelligence system designed to support the discovery of novel substituted phenethylamine compounds. These new molecules are intended for patenting and future development, with potential applications in psychiatric and neurological treatments.
The platform integrates several advanced tools, including a quantitative structure–activity relationship (QSAR) model developed in collaboration with the University of Windsor. This project was supported by funding from the Ontario Centres of Innovation. Alongside the QSAR model, the platform also uses chemical pathway modelling tools powered by AI. Together, these technologies enable the identification, evaluation, and patenting of new compounds within the broader MDXX category.
The goal of Phenesafe AI is to streamline the process of discovering new therapeutic compounds by identifying appropriate molecular targets, assessing chemical synthesis feasibility, and aligning with treatment objectives such as safety and clinical function.
The platform reflects PharmAla’s strategic approach to drug development, which centres on:
- Building strong expertise within a specific drug class
- Leveraging regulatory advantages in the MDXX space
- Prioritising safety pharmacology
- Creating solutions for conditions with limited treatment options
Phenesafe AI is expected to improve both the speed and efficiency of identifying viable drug candidates, supporting PharmAla’s broader mission to deliver innovative treatments for unmet medical needs.
Source: globenewswire.com
